

Summary of Lothian Joint Formulary Amendments

The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The website chapters should be referred to for full details.

The month indicates when Formulary Committee approved the changes.

Note that the formulary recommendations on the new website platform for the East Region Formulary are currently Lothian recommendations only. All of the amendments detailed appear on the new website platform which can be found here: formulary.nhs.scot/east/

January and March 2021

[Home > Therapeutic Areas > Anaesthesia> Peri-operative treatment > Peri-operative analgesia](#) > **Adult mild post-operative pain and moderate post-operative pain**

- In the 'old' LJF layout the formulary included the general term 'NSAID' as an option for peri-operative analgesia. When the old 'LJF' section was mapped to the new formulary layout specific choices were selected. For short term peri-operative use some clinical specialties prefer diclofenac as the NSAID of choice. Diclofenac is now included in the prescribing notes with a reminder that treatment choice should take account of the patient's individual risk factors.

[Home > Therapeutic Areas > Cardiovascular system > Cardiovascular conditions > Hypertension](#) > **Adult Step 1 treatment**

- Lisinopril dose changed as per BNF

[Home > Therapeutic Areas > Central nervous system > Anxiety disorders](#)

- The sertraline 25mg tablet strength is included in all pathways that already have sertraline. This tablet strength is for use in patients in whom a smaller initial starting dose is indicated and for use when gradually stopping treatment.

[Home > Therapeutic Areas > Central nervous system > Depression](#)

- The sertraline 25mg tablet strength is included in all pathways that already have sertraline. This tablet strength is for use in patients in whom a smaller initial starting dose is indicated and for use when gradually stopping treatment.

[Home > Therapeutic Areas > Infections > Urinary tract > Urinary tract infection \(UTI\)](#) > **Adult Lower UTI in pregnant women**

- Revised prescribing notes for alternative antibiotic options in early pregnancy when formulary choices are unsuitable. The current recommendation is to seek microbiology advice if formulary choices are unsuitable. The recommendations are under review by the antimicrobial management team.

[Home > Therapeutic Areas > Infections > Wound and skin > Impetigo > Adult & Child Impetigo](#)

- Flucloxacillin course length changed to 5 days as per FC decision December 2020

[Home > Therapeutic Areas > Infections > Wound and skin > Cellulitis > Adult](#)

Treatment of cellulitis (no systemic symptoms)

- Flucloxacillin course length changed to 5 days as per FC decision December 2020
- Clarithromycin course length changed to 5 days as per FC decision December 2020

[Home > Therapeutic Areas > Malignant disease and immunosuppression >](#)

[Malignant disease > Bone issues associated with malignancy > Adult](#)

prevention of skeletal events in patients with breast cancer

- In order to update in line with local clinical management guidelines, ibandronic acid tablets are moved from first choice to a prescribing note. Zoledronic acid and colecalciferol + calcium carbonate (400unit/600mg OD) is now first choice.
- The dose of colecalciferol + calcium carbonate with denosumab is changed to colecalciferol + calcium carbonate (400unit/600mg OD, including 2 weeks prior to denosumab).
- A prescribing note is added to recommend that colecalciferol + calcium are given during treatment but not if there is hypercalcaemia.

[Home > Therapeutic Areas > Nutrition and blood > Blood > Neutropenia >](#)

Adult treatment of neutropenia

- Following a contract review, filgrastim (Zarzio) is removed and replaced with filgrastim (Accofil). The preferred long acting g-CSF lipegfilgrastim (Lonquex) is removed and replaced with pegfilgrastim (Pelgraz).

[Home > Therapeutic Areas > Obstetrics, gynaecology, and urinary-tract disorders > Genito-urinary > Urinary incontinence > Adult treatment of urinary frequency/urgency](#)

- Removal of prescribing note in relation to product costs as no longer correct due to patent changes.

Additional list (see Formulary Decisions)

- Palbociclib hard capsules discontinued, all strengths changed to tablets.

For details of the Formulary Committee decisions from the meetings on the 20th of January and 3rd of March refer to the [minutes](#) or alternatively search here <https://formulary.nhs.scot/east/formulary-decisions/> with the start date 20 January 2021. See example below:

Lothian Joint Formulary

Search

Q

NHS
SCOTLAND

Therapeutic AreasMedicines A-ZConditions A-ZMedicine CategoriesFormulary Decisions

[Home](#) > [Formulary Decisions](#)

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Generic medicine name

Medicine brand name

Therapeutic area

Please select...

Start date

Wednesday December 16, 2020

End date

Source

Please select...

2020

December

S	M	T	W	T	F	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31		

Lothian

Healthier
Scotland
Scottish
Government

NHS
SCOTLAND

Privacy and cookies
Terms and conditions
Contact us
© Copyright